2023 SOT Award Recipients

Honorary Membership

Namandjé N. Bumpus, PhD

US FDA, Silver Spring, MD

SOT recognizes nonmembers who embody outstanding and sustained achievements in the field of toxicology and/or allied disciplines with Honorary membership.

SOT is pleased to bestow Honorary membership to Namandjé N. Bumpus, PhD, in recognition of her pioneering research in drug metabolism and antiviral pharmacology, as well as her leadership, mentorship, and advocacy, especially regrading diversity, equity, and inclusion.

Dr. Bumpus earned a BA in biology from Occidental College in 2003, which was followed by a PhD in pharmacology from the University of Michigan in 2007. She competed a postdoctoral fellowship at Scripps Research Institute where she researched gene expression and activation of drug metabolizing enzymes. Following her postdoc work, she became an Assistant Professor with the Johns Hopkins University School of Medicine and was appointed E.K. Marshall and Thomas H. Maren Professor and Chair of the Department of Pharmacology and Molecular Sciences in 2020. In August 2022, she became the Chief Scientist for the US Food and Drug Administration (US FDA) where she provides strategic leadership and expertise to support scientific excellence, innovation, collaboration, and capacity to achieve the public health mission of the US FDA.

Though her PhD is in pharmacology, much of Dr. Bumpus’s impressive scientific resume is focused on drug-induced toxicity. Specifically, her research helped identify cytochrome P450-dependent metabolites that produce acute liver failure from antiviral drugs used to treat HIV and hepatitis C. Recently, her lab has used advancements in single cell technologies to detect RNA, proteins, metabolites, and xenobiotics in individual cells to investigate underlying variability in cellular response to xenobiotics. Dr. Bumpus has published 60+ peer-reviewed articles in high-profile scientific journals like Nature and The Lancet.

During Dr. Bumpus’s time at Johns Hopkins and other institutions, she mentored 15+ graduate students and postdocs, as well as master’s and undergraduate students within her laboratory. Dr. Bumpus also has been an advocate for diversity, equity, and inclusion throughout her career. She was the first Black woman to Chair a Johns Hopkins University School of Medicine department and significantly increased the department’s number of women and people of color. She has participated in many forums on racism and sexism in science and received a grant in 2021 to support Black, Latinx, and Indigenous graduate students in drug discovery and development.

Dr. Bumpus has been recognized throughout her career by the scientific community. Most notably, she received a US Presidential Early Career Award for Scientists and Engineers, was elected a Fellow of the American Association for the Advancement of Science, and is a Member of the National Academy of Medicine. She also is serving as the President-Elect of the American Society for Pharmacology and Experimental Therapeutics and has chaired or served on numerous National Institutes of Health study sections.

Achievement Award

John Daniel Clarke, PhD

Washington State University, Spokane, WA

This award recognizes an SOT member who has made significant contributions to toxicology within 15 years of obtaining their highest earned degree.

John Daniel Clarke, PhD, has received the 2023 SOT Achievement Award in recognition of his research in precision medicine and environmental toxicology.

Dr. Clarke received his PhD in molecular and cellular biology from Oregon State University in 2011 and completed a postdoctoral fellowship in pharmacology and toxicology at the University of Arizona. While in Arizona, he served as a member of the university’s Southwest Environmental Health Sciences Center. Since 2016, Dr. Clarke has been associated with Washington State University, first holding the position of Assistant Professor and currently Associate Professor within the Department of Pharmaceutical Sciences. He has been an Affiliate of the University of Washington Center for Exposures, Diseases, Genomics, and Environment since 2017.

Dr. Clarke’s novel hypotheses have expanded prior understanding of (1) altered pharmacokinetics in non-alcoholic fatty liver disease and steatohepatitis, (2) interactions of natural products and liver disease, and (3) pathogenesis of liver cancer due to harmful algal bloom toxins. At the center of these research areas is the critical role of xenobiotic transporters. Dr. Clarke has demonstrated the effect of disease on the pharmacokinetics of hyperlipidemic drugs, including simvastatin, pravastatin, and the antidiabetic drug metformin. By using nutritional, disease, and transgenic animal models, he has untangled various interactions that provide key foundational knowledge in extrapolating to human liver disease and pharmacologic outcomes. Where possible, Dr. Clarke has extended his work to human research, including his investigation of impaired N-linked glycosylation of transporters and dysregulation of carcinoma-related gene networks in diseased human livers. These pivotal studies demonstrate his high commitment to translational toxicology research.

Central to Dr. Clarke’s productivity has been the attainment of significant extramural funding. After arriving at Washington State University with a National Institutes of Health (NIH) K99/R00 Pathway to Independence Award, he continued to investigate mechanisms of microcystin toxicity and its promotion of hepatocellular carcinoma. As a result, he was recognized as a National Institute of Environmental Health Sciences Outstanding New Environmental Scientist. In 2020, he was awarded an NIH R21 grant from the National Center for Complementary and Integrative Health (NCCIH) to explore transporter mechanisms of natural product–drug interactions as well as an NIH R56 grant from NCCIH to investigate xenobiotic-drug interactions in chronic disease. Within the NCCIH U54 Center of Excellence for Natural Product Drug Interaction Research, Dr. Clarke serves as Co-investigator for the Pharmacology and Analytical Cores.

This productivity is complemented by Dr. Clarke’s equally strong publication record in highly regarded journals, including Chemosphere, Journal of Pharmacology and Experimental Therapeutics, and Phytotherapy Research. His research publications have an h-index of 17 on Scopus, and there are 10 papers with more than 40 citations. Dr. Clarke’s review article from 2008 on the anticancer properties of sulforaphane has well over 400 citations. Dr. Clarke’s extensive teaching and mentoring experience show that he is committed to the education of the next generation of scientists across the spectrum. He participates as an instructor in three courses offered by the department—all aligned with his expertise in pharmacology and toxicology. Thus far, Dr. Clarke has been an advisor to more than three dozen students, ranging from undergraduates and interns to doctoral and postdoctoral candidates.

An SOT member since 2012, Dr. Clarke has actively served in a variety of roles, especially within the SOT Mechanisms Specialty Section. He is currently Vice President in the SOT Pacific Northwest Regional Chapter. He also holds memberships in the American Society for Pharmacology and Experimental Therapeutics and the International Society for the Study of Xenobiotics. Also of note, Dr. Clarke has been highly engaged in academic service at Washington State University, serving on more than 12 university steering, recruiting, and advisory committees since 2017.

Arnold J. Lehman Award

Elaine M. Faustman, PhD, DABT, ATS

University of Washington, Seattle, WA

This award recognizes an SOT member who has made a major contribution to risk assessment and/or the regulation of chemical agents, including pharmaceuticals. The contribution may have resulted from the application of sound scientific principles to regulation and/or from research activities that have significantly influenced the regulatory process.

Elaine M. Faustman, PhD, has been awarded the 2023 SOT Arnold J. Lehman Award for her contributions to regulatory toxicology and toxicological risk assessment that have had a global impact during her nearly 50 years in the field.

After obtaining her PhD from Michigan State University, Dr. Faustman’s academic career began in 1983 as one of the first faculty hires in the University of Washington’s then-new toxicology doctoral program in the Department of Environmental Health. One of her enduring contributions to the curriculum was the first graduate-level course on risk assessment of chemical hazards in the US, which she developed and co-taught. She has continued to teach this highly popular course every year since then, and the course draws students from many departments across the university campus, including public affairs, engineering, and genomics. It has impacted well over 1,000 graduate students from an array of disciplines at the university.

Beyond the classroom, Dr. Faustman is actively engaged in training new scientists in risk assessment. She has directly mentored 25 doctoral students, 44 master’s students, 10 postdoctoral scholars, and 18 visiting scientists from 14 different countries. Nearly all these individuals are employed in risk assessment positions in government, industry, and academia in the US and throughout the world.

But her contribution to regulatory toxicology and risk assessment extends well beyond her teaching and training. In the mid-1980s, Dr. Faustman made major contributions to chemical risk assessment through various contracts from the US Environmental Protection Agency (US EPA), such as the incorporation of benchmark-dose modeling that eventually shaped the US EPA risk assessment procedures and policies for decades to come. Her introduction of the benchmark-dose approach to quantitative risk assessment has had a major impact globally on regulatory toxicology.

In addition to her scientific influence on US EPA risk assessment procedures, Dr. Faustman has contributed her expertise globally through participation in many invited committees and workshops from European organizations such as the World Health Organization, International Agency for Research on Cancer, and HESI and regulatory agencies in Australia and China. She also was one of the first participants in the International Union of Toxicology (IUTOX) Risk Assessment Summer School and later went on to be a faculty member for many years. Dr. Faustman’s remarkable breadth of knowledge in molecular toxicology and practical risk assessment procedures and processes makes her the go-to expert for many national and international expert committees appointed to address issues of public health importance, relying on state-of-the-art risk assessment approaches. In addition to serving for six years on the US EPA Science Advisory Board, Dr. Faustman also served on the National Institute of Environmental Health Sciences National Toxicology Program Board of Scientific Counselors, as well as on several important National Academy of Sciences committees and international organizations.

Further, Dr. Faustman’s 250 publications are a testament to her wealth of knowledge in a number of scientific fields. She is the sole author (initially with Gil Omenn as a co-author) of the risk assessment chapter in the fifth through ninth editions of Casarett and Doull’s Toxicology textbook. She also has contributed to nearly 30 other book chapters. She is currently a reviewer of manuscripts submitted to several scientific journals, among them the American Journal of Epidemiology; Applied Occupational and Environmental Hygiene Journal; Aquatic Toxicology; and Carcinogenesis and Mutagenesis. Dr. Faustman is a well-cited scientist and is held in high respect by her peers in the scientific community.

Within SOT, Dr. Faustman is widely recognized for her many contributions to risk assessment, including serving as 2011–2012 President of the Risk Assessment Specialty Section and on the early SOT Risk Assessment Task Force from 2000 to 2002. Dr. Faustman’s impact on risk assessment is further illustrated by her numerous international awards for her contributions in this area, including the 2020 Narsingh Agnish Fellowship Award from the Society for Birth Defects Research and Prevention, 2014 Society for Risk Analysis Distinguished Achievement Award, and the 2019 IUTOX Merit Award.

Distinguished Toxicology Scholar Award

Anumantha G. Kanthasamy, PhD

University of Georgia, Athens, GA

This award recognizes an SOT member who has made substantial and seminal scientific contributions to the understanding of the science of toxicology and is actively involved in toxicological research.

Anumantha G. Kanthasamy, PhD, is awarded the 2023 SOT Distinguished Toxicology Scholar Award for his service to the fields of toxicology and neuroscience and particularly for his leadership in unraveling novel signaling pathways contributing to neurotoxicity and Parkinson’s disease.

Dr. Kanthasamy received his undergraduate and PhD education in biochemistry in India at the University of Madras and then conducted postdoctoral training in medicinal chemistry and molecular pharmacology at Purdue University in Indiana. After completing his junior faculty position in the Department of Neurology and Environmental Health at the University of California Irvine, he rose through the ranks of the Department of Biomedical Sciences at Iowa State University from 2011 to 2021, culminating in becoming Distinguished Professor and Chair of the department and appointment as Lloyd Chair and Eminent Scholar in Neurotoxicology. In September 2021, he joined the University of Georgia (UGA) as the John H. “Johnny” Isakson Chair and Georgia Research Alliance Eminent Scholar in the College of Veterinary Medicine Department of Physiology and Pharmacology. He also is the founding Director of the Center for Neurological Disease Research at UGA.

Dr. Kanthasamy’s research expertise has been exceptionally strong in the mechanisms of Parkinson’s disease neurodegeneration. More specifically, he is recognized for his work studying the relationships of protein aggregation and neurotoxicology and disease, mechanisms of misfolded protein propagation, oxidative stress in dopamine neurons, stress signaling, and mitochondrial biology in neurological function. More recently, his work also has contributed to understanding the role of the gut microbiome in neurodegenerative disease. He is widely recognized for his contributions that demonstrate the key roles for protein kinase c-delta in neurodegenerative disease.

In 2006, Dr. Kanthasamy founded the Iowa Center for Advanced Neurotoxicology (ICAN) and continues to serve as its Director. ICAN was established to promote both basic and translational neurotoxicological research among neuroscientists, pharmacologists, and toxicologists at Iowa State University. At ICAN, he directed the Presidential Interdisciplinary Research Initiative titled Big Data Brain Initiative, which researched Parkinson’s and Alzheimer’s disease.

As an indicator of external recognition of his scientific excellence, Dr. Kanthasamy’s research program has been supported by over $30 million in funding, including three active R01 and two U01 grants from the National Institute of Environmental Health Sciences (NIEHS), National Institute of Neurological Disorders and Stroke (NINDS), and National Institute on Aging where he serves as Principal Investigator (PI), as well as a US Department of Defense Congressionally Directed Medical Research Program grant as PI, and other active funding. He holds additional grants from the Michael J. Fox Foundation and National Institutes of Health (NIH) Small Business Innovation Research grant.

Dr. Kanthasamy is internationally recognized for his work in multiple areas related to neurotoxicity and neurodegeneration. His impact in these areas can be measured by the enormous number of invited presentations of his research worldwide, the number of grant review panels on which he serves, and the sustained publication productivity giving rise to more than 180 published manuscripts in the top journals in toxicology and neuroscience. He has an h-index of 71 and an i-10 index of 180 according to Google Scholar in December 2022. The h-index indicates at least 64 of his papers have been cited at least 64 times in the literature, and 170 publications have been cited at least 10 times. His work has been cited a total of 25,503 times.

Dr. Kanthasamy also founded two biotech companies aimed at translating his research from the laboratory to the clinic to develop therapeutic and diagnostic strategies for neurodegenerative diseases.

In addition to his distinguished research and publications, Dr. Kanthasamy has an impressive track record of training PhD students. He has mentored more than 30 doctoral students who have won more than 200 awards, published high-impact papers, and gone on to careers at top institutions in academia, industry, and government.

Dr. Kanthasamy served as Vice President and President of the SOT Neurotoxicology Specialty Section. Dr. Kanthasamy was elected Fellow of the American Association of the Advancement of Science in 2015, Fellow of the Academy of Toxicological Sciences in 2015, and Fellow of the National Academy of Inventors in 2021. Dr. Kanthasamy has served on five Editorial Boards focused on toxicology and neuroscience, including serving as an Associate Editor for Toxicological Sciences and is an ad hoc reviewer for countless journals. Finally, he is a reviewer for a multitude of study sections for NIEHS and NINDS. He has been a permanent member on multiple study sections for NIH and served as an ad hoc reviewer for more than 20 panels since 2016.

Education Award

Bevin Page Engelward, ScD

Massachusetts Institute of Technology, Cambridge, MA

This award recognizes an individual who is distinguished by the teaching and training of toxicologists and who has made significant contributions to education in the broad field of toxicology.

Bevin Page Engelward, ScD, has received the 2023 SOT Education Award as an outstanding educator for her leadership in the lab, classroom, and the field through her work with Superfund Research Program (SRP).

Dr. Engelward holds an ScD degree from the Harvard T.H. Chan School of Public Health, where she also completed a postdoctoral fellowship before joining the Massachusetts Institute of Technology (MIT) as an Assistant Professor in 1997. Currently, she serves as Professor in the MIT Department of Biological Engineering, a position she has held since 2014, and as the Director of the MIT SRP.

As an example of her interdisciplinary approach to teaching and training, Dr. Engelward serves as a mentor to the SRP trainees. The students learn about specific Superfund Sites, the chemical contamination problems associated with those sites, and the ways that researchers are helping to find solutions to these important public health challenges. Students learn about the value, importance, and challenges associated with interdisciplinary collaborations, as well as strategies for communicating across disciplines more effectively. Also folded into the curriculum are trainee workshops that focus on a wide array of topics, including (1) how to write a research manuscript, (2) the importance of communicating to the public in lay language, and (3) strategies for shaping a career around one’s passions.

At MIT, the students evaluate their professors and their coursework on a 1–7 scale. Dr. Engelward scores a 6.4–6.8 on average in this competitive ranking system. One of her key accomplishments is that she has brought her research, along with fundamental concepts in toxicology, directly to the classroom. In one of her courses, students do hands-on experiments that mirror those that are ongoing in Dr. Engelward’s laboratory and use cutting-edge technology developed in her lab. In the words of her students, Dr. Engelward has the “ability to blend basic science with public health and community needs, including in the examples she used in teaching...” and offers “great insights into many facets of genome stability covering a breadth of medical applications, public health interventions, and more! She offers a great combination of technical lectures and discussions.” As a lecturer, Dr. Engelward is in high demand, having delivered over 150 presentations thus far in her career.

Dr. Engelward has mentored and educated more than 40 graduate students and postdoctoral trainees over the past 25 years at MIT. Many of her students are now embarking on or leading successful careers in toxicology and the life sciences.

Dr. Engelward’s research includes studies of the relationship between DNA repair and disease susceptibility; the creation of genetically engineered mice for studying exposure-induced mutations in vivo; and the creation of novel high-throughput platforms for measuring DNA damage, DNA repair, and cytotoxicity in human cells. Dr. Engelward also is a co-inventor on two US patents: “Systems and Methods for Volumetric Tissue Scanning Microscopy” and “CometChip: Electrophoresis of Arrayed Cells for Analysis of DNA Damage and Repair.”

Dr. Engelward is an SOT member and has served as an SOT Scientific Session Chair. She is a Past President of the Environmental Mutagenesis and Genomics Society.

Enhancement of Animal Welfare Award

Erin H. Hill, BA

Institute for In Vitro Sciences Inc., Gaithersburg, MD

This award recognizes an SOT member for contributions made to the advancement of toxicological science through the development and application of methods that replace, refine, or reduce the need for experimental animals. This award recognizes outstanding/significant contributions made by SOT members to the scientifically sound and responsible use of animals in research. This award also serves to recognize member contributions to the public awareness of the importance of animals in toxicology research. The achievement recognized may be either a seminal piece of work or a long-term contribution to toxicological science and animal welfare.

Erin H. Hill, BA, has received the 2023 SOT Enhancement of Animal Welfare Award for her decades of work to advance both science and animal welfare. Ms. Hill leads efforts and forms partnerships with industry, government, and non-governmental organizations around the world to collaborate on the implementation of approaches that aim to improve the reliability and relevance of toxicology testing. She is internationally recognized and well-respected in the field of alternatives to animal testing.

Ms. Hill co-founded the nonprofit Institute for In Vitro Sciences Inc. (IIVS) in 1997 and currently serves as its President. IIVS is dedicated to advancing alternative methods and positively impacting animal welfare regulations. Ms. Hill’s leadership at IIVS has helped make it universally recognized as a respected organization that is a leader in the field of in vitro toxicology testing that vigorously promotes the use and acceptance of new approach methods (NAMs) worldwide.

Ms. Hill has developed IIVS into a uniquely qualified team of experts with hands-on expertise in conducting and interpreting data from in vitro methods who provide—often free of charge—training opportunities for other scientists around the world. As just one example, Ms. Hill started the Practical Methods for In Vitro Toxicology Workshop during which scientists and regulators attend lecture-style and hands-on laboratory trainings; this program has reached hundreds of scientists who then take their learnings back to their organizations for an even larger impact. She also co-created and leads the IIVS Industry Council for the Advancement of Regulatory Acceptance of Alternatives that focuses on international acceptance of in vitro methods.

Under Ms. Hill’s leadership, since 2014, IIVS has worked with the China Food and Drug Administration (CFDA) to assist them in adopting non-animal tests for the registration of cosmetics. A vital component of the memorandum of understanding that IIVS has with CFDA is to provide in-depth training for provincial regulators. One early success of this collaboration was the acceptance by the CFDA of the in vitro 3T3 Neutral Red Uptake Phototoxicity Assay. This achievement was recognized by the inaugural LUSH Training Prize.

Ms. Hill also has been involved in training sessions in Vietnam, Japan, and Brazil, demonstrating her global influence.

Ms. Hill has been active SOT member since 1990 through engagement with multiple SOT Specialty Sections, serving as a Chair for Scientific Sessions, and presenting lectures during SOT events. She also is a co-founder, a board member, and the treasurer of the American Society for Cellular and Computational Toxicology and a board member of the European Society for Toxicology In Vitro, the In Vitro Testing Industrial Platform, and the Johns Hopkins University Center for Alternatives to Animal Testing and holds leadership positions with numerous other organizations.

Founders Award (for Outstanding Leadership in Toxicology)

Jon C. Cook, PhD, DABT, ATS

Pfizer Inc., Groton, CT

This award, sponsored by the SOT Endowment Fund, recognizes a Full, Emeritus, or Retired Full member who has demonstrated outstanding leadership in fostering the role of toxicological sciences in safety decision-making through the development and/or application of state-of-the-art approaches that elucidate, with a high degree of confidence, the distinctions for humans between safe and unsafe levels of exposures to chemical and physical agents.

Jon C. Cook, PhD, DABT, ATS, is the recipient of the 2023 SOT Founders Award (for Outstanding Leadership in Toxicology) in recognition of his career in industry that has focused on human health and risk assessment supported by state-of-the-science research.

Dr. Cook earned his PhD in toxicology from North Carolina State University, followed by a postdoctoral fellowship at the Chemical Industry Institute of Toxicology (CIIT) in Research Triangle Park, North Carolina. At CIIT, he began work on the toxic mechanisms of dioxin that would directly inform dioxin’s human health risk assessment. He then spent 11 years as a Research Toxicologist with DuPont-Haskell Laboratory for Toxicology and Industrial Medicine, starting his research on endocrine-related issues and carcinogenicity of chemicals. Dr. Cook, his laboratory, and his collaborators made several important contributions to the development of screening batteries and risk assessment methods for endocrine-disrupting chemicals at a period in the history of toxicology when the science was just evolving. He also was one of the first to identify mechanisms of carcinogenicity of peroxisome-proliferating chemicals and drugs and for perfluorinated chemicals, which remains a major issue in public health to this day.

Since 1998, Dr. Cook has been with Pfizer Inc. where he is Vice President of Scientific Research and Chief Toxicology Scientist. At Pfizer, Dr. Cook has extended his expertise in mechanisms of carcinogenicity to the study of hemangiosarcomas. He collaborated with major researchers in the field to develop a body of work that showed the lack of relevance of rodent hemangiosarcomas to human health and allowed rational regulation and use of drugs that caused rodent hemangiosarcomas. Dr. Cook also continued research in developmental and reproductive toxicology, contributing to several publications on this topic, particularly on COX inhibitors and their developmental toxicity. He continues to be active in the developmental and reproductive toxicology area with endocrine-related research publications and a recent book chapter.

Regarding his scientific leadership, Dr. Cook has both a broad and deep understanding of toxicological sciences ranging from traditional histopathology to state-of-the-art approaches such as microphysiological systems and machine learning. He has a compelling interest in novel science and has always been very supportive of new approaches even if their use is not immediately apparent. For example, Dr. Cook was a strong advocate of introducing what were once considered new molecular biology techniques, such as cloning and polymerase chain reaction, to help elucidate the mode of action for peroxisome proliferators. Dr. Cook, among others, used his considerable expertise and inclusive style to bring in a new way of thinking which led to an international consensus on mode of action and the associated species differences in the response to peroxisome proliferators and implementation of risk assessment guidelines to ensure safe levels of exposure. Dr. Cook has published his research extensively from 1983 through 2022 in leading journals, the most recent on drug-induced liver injury that utilized machine learning to compare the predictive performance of in vitro assays versus physicochemical parameters.

Dr. Cook has contributed his expertise to SOT in numerous roles, including SOT 2011–2012 President, SOT Carcinogenesis Specialty Section President, SOT Workshop Session Co-Chair, and SOT Committee roles. He is Past President of HESI. He also has been active in the International Life Sciences Institute and the National Institute of Environmental Health Sciences.

Leading Edge in Basic Science Award

Irfan Rahman, PhD

University of Rochester Medical Center, Rochester, NY

This award recognizes a scientist who, based on research, has made a recent (within the last five years), seminal scientific contribution/advance to understanding fundamental mechanisms of toxicity. The recipient should be a respected basic scientist whose research findings are likely to have a pervasive impact on the field of toxicology.

Irfan Rahman, PhD, has received the 2023 SOT Leading Edge in Basic Science Award for his contributions and advances in pulmonary toxicological sciences, specifically for his unwavering commitment to investigating how electronic cigarettes and cigarette smoke cause lung injuries and disease in humans, focusing on the fundamental alterations of DNA damage and cellular senescence.

Dr. Rahman holds a PhD in biochemistry on neutrophil functions from the University of Nagpur, India. He completed a postdoctoral fellowship on lung toxicology at the University of Miami and Georgetown University before relocating to the University of Edinburgh, where he focused on environmental agents and lung inflammation and received an appointment as a Senior Research Scientist/Lecturer. In 2003, Dr. Rahman joined the faculty of the University of Rochester Medical Center Department of Environmental Medicine where he has risen through the faculty ranks with appointments with the Department of Public Health Sciences, Division of Pulmonary and Critical Care Medicine, and Eastman Institute for Oral Health. Since 2018, he has been the Director of the Center for Inhalation and Flavoring Toxicological Research.

The research program that Dr. Rahman has developed unites the fields of circadian biology, chromatin remodeling, inflammation, sirtuin1 deacetylase (SIRT1) dynamics, and oxidants related to the impact of tobacco products on lung toxicology. He has been a longstanding pioneer with seminal contributions and cutting-edge research on mitophagy, steroid resistance, and lung cellular senescence and is a leader in the role of oxidative stress and redox signaling in gene transcription in tobacco-related pulmonary diseases. In addition, he also has been a leader in the molecular biology of chromatin remodeling and cellular senescence in the lung in response to oxidative stress and cigarette smoke and was the first to show chromatin remodeling and cellular senescence in the lung in response to cigarette smoke. He has identified several exciting potential therapies that could prevent tobacco-related lung complications from progressing.

Dr. Rahman’s mechanistic discoveries and experience translated rapidly to address major issues for human health in the past five years, namely COVID-19 and e-cigarette toxicity. Of critical importance, he is constantly evolving his research to meet the challenging landscape of tobacco/e-cigarette products for lung health. For example, with regard to the rapid emergence of e-cigarettes in the high school population and the hookah waterpipe tobacco bars in college communities, Dr. Rahman already has published several papers on these products. During the pandemic, Dr. Rahman worked on COVID-19 biospecimens and showed that smokers/vapers are more susceptible to infection and are more likely to develop strong lung inflammatory response via upregulation of ACE2 via nicotine receptor alpha 7, particularly in older individuals.

Dr. Rahman’s publications list consists of 225 original papers, 90 reviews, and 25 book chapters with an h-index of 110 with more than 50,000 citations; he also was selected for a list of Highly Cited Researchers by Thomson Reuters in 2014, 2015, and 2016. He has been recognized internationally and is ranked 16 of 52,718 active respiratory and allergy researchers by Ioannidis et al. (2020) He is the editor and author of Inflammation, Aging, Diet, and Nutrition, a book published by Elsevier in 2013. During his career, he has held 21 Associate Editor and Editorial Board memberships and has reviewed articles for more than 50 journals. In addition, he is the Principal Investigator on four National Institutes of Health grants.

Dr. Rahman has devoted his career to teaching, understanding, and the prevention/treatment of smoking-related lung diseases. Over the years Dr. Rahman has mentored eight full-time graduate students, 30 postdoctoral scholars, and four undergraduate students, several of whom are now prominent faculty members at various institutions.

Dr. Rahman has attended the SOT Annual Meeting and ToxExpo regularly since 2003 and has been an SOT member since 2005. He has continuously provided leadership in SOT, serving as a Councilor and President of the SOT Inhalation and Respiratory Specialty Section. He also has been involved in the American Thoracic Society as a Program Committee member for the Respiratory Cell and Molecular Biology (RCMB) Assembly and created the Lung Aging Research Interest Group in the RCMB Assembly. In 2022, he received an American Thoracic Society Recognition Award for Scientific Accomplishments.

Merit Award

Lois D. Lehman-McKeeman, PhD

Bristol Myers Squibb, Princeton, NJ

This award recognizes an SOT member who has made distinguished contributions to toxicology throughout an entire career in areas such as research, teaching, regulatory activities, consulting, and service to the Society.

Lois D. Lehman-McKeeman, PhD, has been awarded the 2023 SOT Merit Award in recognition of her distinguished career in private industry focusing on research in toxicology and drug metabolism, including mechanisms of toxicity and carcinogenicity of xenobiotics.

In 1986, Dr. Lehman-McKeeman received her PhD in toxicology from the University of Kansas Medical Center. From there, she began her career at Procter & Gamble as a Research Scientist with increasing responsibilities for mechanistic research in biochemical toxicology and xenobiotic metabolism. In 2001, she joined Bristol Myers Squibb in discovery toxicology, and she is currently Vice President of Pharmaceutical Candidate Optimization, overseeing a multidisciplinary department whose research supports drug candidate selection for clinical progression.

Dr. Lehman-McKeeman is most recognized for research that identified the mode of action by which certain chemicals induced kidney tumors in male rats. Her work demonstrated the reversible binding of d-limonene-epoxide, a metabolite of d-limonene, to the male rat specific protein α2u-globulin (α2u). Her team derived the x-ray crystal structure of α2u and determined how the protein complex accumulated in proximal tubules of male rats exposed to d-limonene. Dr. Lehman-McKeeman’s research on this pathway provided seminal data to inform and support risk assessments that humans who do not synthesize α2u are not at risk of kidney cancer if exposed to chemicals that induce α2u nephropathy. This research has been published in several reviews and applied by regulatory agencies to develop criteria to confirm the lack of relevance for human cancer risk. This research represents one of the first examples by which lack of human relevance was established for rodent carcinogens. Although α2u nephropathy is a major example, Dr. Lehman-McKeeman’s career has focused on defining mechanisms of toxicity and carcinogenesis, and her research teams have made important contributions to environmental chemical and pharmaceutical risk assessments.

Dr. Lehman-McKeeman’s bibliography over a 35-year career includes 20 book chapters in prominent toxicology reference books regarding various molecular mechanisms underlying disease outcomes or drug disposition; more than 100 full-length manuscripts; and 77 invited presentations (international and national and from across academia, government, and private industry).

Dr. Lehman-McKeeman has been appointed to external advisory committees for the US Environmental Protection Agency, the International Agency for Research on Cancer, and the American Water Works Association Research Foundation. She also has served in Adjunct Associate Professor roles, and she has mentored students and postdoctoral scholars throughout her career. She is recognized as a role model and mentor to colleagues and staff through leadership roles in her work and within SOT, including supporting education initiatives and the career development of toxicologists at all levels.

Dr. Lehman-McKeeman has a long history of elected service to SOT, beginning in 2000 as an SOT Councilor and culminating as SOT President 2013–2014. She currently serves on the SOT Nominating Committee. She previously received the SOT Achievement Award, the Career Achievement Award from the SOT Mechanisms Specialty Section, and the SOT Founders Award (for Outstanding Leadership in Toxicology). She also is an American Association for the Advancement of Science Fellow.

Possibly, her most significant contributions to SOT were during her tenure as Editor-in-Chief of Toxicological Sciences (2002–2011). Her vision for the journal was to be the premiere toxicology journal with goals of improving its impact factor and the number of articles published. Dr. Lehman-McKeeman was successful in achieving these goals and is credited for improving the ranking of the Society’s journal from an impact factor of 3.26 to 5.18 by the end of her term.

Public Communications Award

Jamie C. DeWitt, PhD

East Carolina University, Greenville, NC

The SOT Public Communications Award is presented to recognize an individual who has made a major contribution to broadening the general public’s awareness of toxicological issues, including public understanding of the role and importance of experimental animals in toxicological science, through any aspect of public communications, over a significant period of time.

Jamie C. DeWitt, PhD, is the 2023 recipient of the Public Communications Award. Her work over the last 15+ years in emerging contaminants has allowed her to effectively inform policy and the communications arena with respect to foundational science and their application to state and federal health guidelines, including facilitation, interpretation, and communication to enhance interactions with members of impacted communities.

Dr. DeWitt earned a PhD in environmental science and a PhD in neural science from Indiana University in 2004, with a concentration in environmental and developmental neurotoxicology and risk assessment. Since 2015, she has taught at East Carolina University (ECU) in the Department of Pharmacology and Toxicology, where she currently holds the position of Professor. At ECU, Dr. DeWitt has developed a research program that focuses on how exposure to environmental contaminants alters the health status of living organisms. Her scholarship is dedicated to understanding the toxicological effects of emerging environmental contaminants, including per- and polyfluoroalkyl substances (PFAS), geogenic dusts, and pharmaceutical and personal care product pollutants.

Dr. DeWitt is recognized as a global expert in immunotoxicology, especially with respect to PFAS. Her expertise has been utilized by the International Agency for Research on Cancer, the US Environmental Protection Agency, the US National Toxicology Program, and the Agency for Toxic Substances and Disease Registry as an external reviewer or author of documents that the agencies have produced related to PFAS. Dr. DeWitt has testified before subcommittees of the US House of Representatives on PFAS toxicity, served/serves as an expert witness in legal cases surrounding PFAS, and provides pro bono consultation to a wide variety of advocacy organizations on PFAS toxicity. On the local level, she is involved in the North Carolina State University P42 Superfund Research Program Center examining the immunotoxic effects of legacy PFAS chemicals and newer GenX compounds that affect the Cape Fear River in North Carolina.

Because she is regarded as an effective public speaker, since 2018, Dr. DeWitt has delivered, on average, 10 invited public presentations/seminars per year. Her early work and suggested initiatives have spurred epidemiological evaluation of PFAS effects on vaccine efficacy, response to COVID severity, and other work in the immunotoxicity field. Currently, epidemiological evidence for immune targets is driving US regulatory policymaking for the PFAS chemicals PFOA and PFOS.

Dr. DeWitt is an effective communicator in the classroom as well, teaching graduate introductory and advanced toxicology, biomedical statistics, pharmacology (undergrad/grad/med students), and parts of the biomedical sciences introductory course, covering pharmacology and developmental health effects. For her continued excellence in research and teaching, she has received the East Carolina University 2017 Faculty Mentor Award from the Honors College and the 2021 Scholar-Teacher Award from the Office of Faculty Excellence.

Dr. DeWitt has been an SOT member since 2005. She has served in leadership positions in the SOT North Carolina Regional Chapter and is Past President of the SOT Immunotoxicology Specialty Section. She is an Associate Editor for Toxicology and Applied Pharmacology and Editorial Board member of several other top toxicology journals.

Toxicologist Mentoring Award

Robyn Leigh Tanguay, PhD

Oregon State University, Corvallis, OR

This award recognizes an SOT member who has displayed a commitment to mentoring and whose advice and counsel have substantially enhanced the career development of toxicologists.

Robyn Leigh Tanguay, PhD, has been awarded the 2023 SOT Toxicologist Mentoring Award for her commitment to mentoring and advancing the careers of dozens of toxicologists thus far in her career.

Dr. Tanguay is a University Distinguished Professor in the Department of Environmental and Molecular Toxicology and Director of the Sinnhuber Aquatic Research Program at Oregon State University. She received her BS from California State University San Bernardino and her PhD from the University of California Riverside in biochemistry. She is a leader in the field of systems toxicology and a pioneer in using zebrafish as a model for predictive toxicology.

Over the last 22 years, the statistics on individuals under Dr. Tanguay’s mentorship are as follows: 35 graduate students, 18 postdoctoral scholars, and more than 40 undergraduates conducting research in her lab. In addition, Dr. Tanguay has served on 37 graduate committees. All her trainees have gone on to pursue established careers within government, industry, and academia.

In the past five years, Dr. Tanguay has been working to mentor more individuals into positions in academia. To accomplish this, she has been sharing her experience and journey working in academia with many postdoctoral groups to encourage them to have a career in academia. She educates and explains how the process works and is very forthright about the opportunities, challenges, and personal characteristics necessary to succeed. Dr. Tanguay also is supportive of all postdoctoral scholars who want to write grants. She makes herself accessible to serve on their committee and helps connect them with her network of researchers to facilitate their success.

Also, of note, Dr. Tanguay fosters collaborations across scientific fields in all her projects and makes a point to immerse mentees in collaborative experiences. This has greatly benefited mentees’ scientific knowledge base, ability to communicate across specialties, and networking skills. She encourages her students to pursue leadership positions at the university and in professional organizations such as SOT.

She has been associated with SOT for more than 20 years. She is a member of councils and boards of numerous organizations, including SOT Council.

Translational Impact Award

Kjersti Aagaard, MD, PhD

Baylor College of Medicine, Houston, TX

This award recognizes a scientist whose recent (within the last 10 years) outstanding clinical, environmental health, or translational research has improved human and/or public health in an area of toxicological concern.

Kjersti Aagaard, MD, PhD, has received the 2023 SOT Translational Impact Award in recognition of her achievements in elucidating the underlying molecular mechanisms that link environmental and nutritional exposures during pregnancy and early development to later childhood and adult disease. Her work has significantly contributed to the understanding of the genomic and epigenomic mechanisms underlying the developmental origins of health and disease.

Dr. Aagaard received her PhD in immunology from the Mayo Clinic School of Graduate Medical Education in 1996, her MD from the University of Minnesota in 2000, and her master’s in clinical investigation from the University of Utah in 2007. She completed a residency in obstetrics and gynecology and a fellowship in maternal-fetal medicine. From there, she joined the faculty at Texas Children’s Hospital, Baylor College of Medicine. Dr. Aagaard currently holds the Henry and Emma Meyer Professor & Endowed Chair in Obstetrics and Gynecology at Texas Children’s Hospital, Baylor College of Medicine. She also serves as Vice Chair of Research for Obstetrics & Gynecology and is a Professor in the Departments of Molecular and Human Genetics, Molecular and Cellular Biology, and Molecular Physiology and Biophysics. Additionally, she is an Associate Director in the Baylor College of Medicine MSTP MD PhD program.

Her clinical interests include emerging obstetrical infectious diseases, preterm birth, diabetes, and hypertensive disorders in pregnancy; maternal smoking and environmental exposures; and the detection and diagnosis of congenital and genetic anomalies. Her clinical and translational research interests parallel her clinical interests and focus on the role of the microbiome in pregnancy and early developmental programming and the effects of key exposures in pregnancy (such as nutrition, diabetes, maternal high-fat diet, smoking, and environmental chemical exposures) on fetal development and later-in-life disease. Her laboratory also is engaged in understanding the development and impact of perturbation on the microbiome and the effect of gene-environment interactions (including environmental toxicant exposures) on maternal-fetal outcomes and infant health. Her research has yielded groundbreaking advances in medicine and science, specifically as it relates to how our environment can have lasting impacts on the health of infants and children.

During her studies, she established several unique resources for the broader research community. Two examples of these are PeriBank, which is a fully integrated universal database and perinatal biospecimen repository developed and managed under her direction at Texas Children’s Hospital, Baylor College of Medicine and supported by Texas Children’s Hospital, and the generation of several unique National Institutes of Health (NIH)–funded nonhuman primate models for environmental exposure studies during pregnancy—Dr. Aagaard and collaborators at the Oregon National Primate Research Center have spent two decades developing models that have established the current paradigms of maternal exposures rendering disrupted fetal programming.

Most recently, Dr. Aagaard’s research has focused on understanding environmental influences on preterm birth. As a Project Lead for the Baylor College of Medicine-Rice University P42 Superfund Research Program, Dr. Aagaard is exploring how proximity to superfund sites increases the probability of preterm birth. Her work is exploring links between maternal exposure to polycyclic aromatic hydrocarbons and risk for preterm birth, as well as how these exposures incrementally augment major morbidities associated with preterm birth, such as bronchopulmonary dysplasia (chronic lung disease) in premature infants.

She has more than 250 publications in journals such as Nature, Nature Medicine, Nature Communications, New England Journal of Medicine, Proceedings of the National Academy of Sciences, Environmental Health Perspectives, and Science Translational Medicine and has presented more than 400 abstracts. She has received numerous award recognitions for her research: the NIH Director’s New Innovator Award in 2007, the Baylor College of Medicine Michael E. DeBakey Medal for Excellence in Research in 2015, the Nature Award for Mentoring in Science in 2018, and the Society for Reproductive Investigation’s President’s Achievement Award in 2020. She also was elected to the American Society for Clinical Investigation in 2019.

In addition to her research efforts, Dr. Aagaard maintains teaching and administrative responsibilities and has served as a mentor to more than 33 graduate students and 13 postdoctoral scholars. She also is a clinician actively practicing maternal-fetal medicine and dedicated in her service to vulnerable communities and lessening the disproportionate burden of maternal and infant morbidity and mortality suffered by these communities around the globe.

Undergraduate Educator Award

Lauren M. Aleksunes, PharmD, PhD, DABT

Rutgers, The State University of New Jersey, Piscataway, NJ

This award, sponsored by the SOT Endowment, recognizes an SOT member who is distinguished by outstanding contributions to the teaching of undergraduate students in toxicology and toxicology-related areas and whose efforts support the Society’s strategic efforts to “build for the future of toxicology.”

Lauren M. Aleksunes, PharmD, PhD, DABT, has been awarded the 2023 SOT Undergraduate Educator Award in recognition of her teaching and mentoring of undergraduate pharmacy students and her significant contributions to the development of new curricula and instructional approaches to attract, educate, and retain students in the field.

Dr. Aleksunes received a PharmD and PhD in pharmacology and toxicology from the University of Connecticut in 2002 and 2006, respectively. She completed a postdoctoral fellowship in pharmacology and toxicology at the University of Kansas Medical Center in 2009. She joined the faculty of Rutgers Ernest Mario School of Pharmacy in 2009 and currently serves as Professor. Also, Dr. Aleksunes is concurrently the Director of the Joint Graduate Program in Toxicology at the university.

The majority of her teaching is to undergraduate students (i.e., juniors and seniors). The Rutgers PharmD program is one of the few programs in the country where most students are accepted into the school while enrolled in high school. As a member of the Pharmacology and Toxicology Department, Dr. Aleksunes teaches in several core courses, including Physiology, Pathophysiology, Pharmacology and Pharmacogenetics, and various Pharmacotherapy Modules. Her primary teaching responsibility is the Pharmacology and Pharmacogenetics course that is held in the junior year; she covers 55% of the content and particularly the toxicological perspective of topics, including dose-response, receptor signaling, regulation of pharmacokinetics/toxicokinetics, and pharmacogenetics/toxicogenetics. She also lectures in other elective courses, such as Introduction to Research and Developmental and Reproductive Toxicology.

In addition to her important contributions to classroom teaching, Dr. Aleksunes has significantly strengthened and expanded the research opportunities available to undergraduate students in the school. In 2010, she took over as Co-director of the Honors Research Program at the school, reorganizing the curriculum and professional activities of undergraduate pharmacy honors students and working with other faculty in the department to establish and promote Rutgers’s now highly successful PharmD/PhD program. Rutgers has graduated five PharmD/PhD students in the field of pharmacology and toxicology, two of whom were trained by Dr. Aleksunes.

She also worked to expand the school’s summer undergraduate research fellowship program, which she has taken over as Director. In addition to developing a more formal didactic program for the summer students, which includes career counseling and an industrial field trip, she was key in the department’s success in obtaining three highly prestigious grants to support the program. These included grants from the American Society for Pharmacology and Experimental Therapeutics (ASPET) and SOT on which she is the Principal Investigator (PI) and a third from the National Institutes of Environmental Health Sciences on which she also serves as PI (currently in year 12 of funding).

Another notable accomplishment under Dr. Aleksunes’s leadership has been the establishment of a pipeline of undergraduate researchers who pursue graduate education in pharmacology and toxicology, particularly students from underrepresented minority backgrounds, as well as those from small colleges without significant research opportunities. To accomplish this, Dr. Aleksunes partnered with the Research Intensive Summer Experience program at Rutgers that supports national recruitment. This pipeline has benefited the Rutgers Pharmacology/Toxicology PhD and postdoctoral program with a third of its trainees from underrepresented backgrounds.

Dr. Aleksunes also has been active in teaching one-on-one in her laboratory, and she holds a reputation as an outstanding teacher and mentor. Her students have won major awards at scientific meetings hosted by SOT and ASPET, and some have received fellowship funding from the National Institutes of Health, the American Foundation of Pharmaceutical Education (AFPE), and the Pharmaceutical Research Manufacturers of America.

Further evidence of her teaching excellence can be found in her recent awards. In 2014, she was selected as a recipient of the highly prestigious Rutgers Presidential Fellowship for Teaching Excellence and in 2015 for the Mentor of the Year Award from AFPE. In 2018, she was awarded the Excellence in Teaching Award from the NJ Health Foundation, and in 2020, she was named the Rutgers University Chancellor’s Educator of the Year. Recognizing her strong commitment to students, the graduating PharmD class of 2021 voted Dr. Aleksunes as the William and Helen Levine Teacher of the Year. Additionally, this year, she received the Rutgers Biomedical and Health Sciences Distinguished Mentor Award.

Toxicological Sciences Paper of the Year Award

Paternal Cannabis Exposure Prior to Mating, but Not Δ9-Tetrahydrocannabinol, Elicits Deficits in Dopaminergic Synaptic Activity in the Offspring.

Theodore A. Slotkin, Edward D. Levin, and Frederic J. Seidler.
2021. Toxicological Sciences 184, no. 2 (December): 252–64. View Abstract

The legalization and increasing availability of cannabis products raise public health concerns about these products; yet, little attention has been paid toward the impact of paternal cannabis use on neurodevelopment in the offspring. Slotkin and colleagues investigated the effects of paternal cannabis exposure by administering cannabis extract to male rats with two cannabis treatment scenarios: (1) “Early Cannabis” rats were treated with cannabis for 28 days and then cannabis was discontinued for 28 days for the ensuing 56 days before mating, and (2) “Late Cannabis” rats were treated for 28 days just before mating. To study the impact on dopamine systems in the brains of offspring, dopamine utilization was measured. Dopamine utilization was calculated as the dihydroxyphenylacetic acid/dopamine ratio since dihydroxyphenylacetic acid is the major metabolite of dopamine. Exposure of paternal cannabis with either treatment caused a profound and persistent deficit in dopamine utilization in the offspring, suggesting reduced presynaptic activity. However, the two treatment scenarios differed in the mechanism; “Early Cannabis” reduced dihydroxyphenylacetic whereas “Late Cannabis” increased dopamine. This novel investigation by Slotkin and colleagues provides evidence for adverse effects of paternal cannabis use on neurodevelopment in offspring. Importantly, the adverse impact of parental drug use is not restricted to maternal exposure—it also can come from the father exposed to cannabis over an extended period before conception. This well-written manuscript has made a significant positive impact to the field of toxicology. The SOT Board of Publications proudly confers the Toxicological Sciences Paper of the Year Award to Slotkin and the entire research team.

GSSEP SCHOLAR

Name, Degrees

Aff, City, State

Invereria cone natur aut ut volo esequat. Aquunt debitiam, nobisiti imincto doluptas explam doluptae. Unt estrunt aut molor reseria conse sit quos unti dollabo reiunt ea assequo te et ilia suntium alia quatem simaximost, ut od erem voloruptat maxim et reriam as nobitae perci blam cum res endic tem que volum qui que acidenes enditis quam, nullatius dolo occus in repel molupitas et aut omnis dunti volupta commo blaceaq uaestia vent remporem explatio temporiam, arupta nam aborehentus santem fugiat aut lati di veni ommodipitae. Um litem quam hicid qui raesecus simodipic to volesciant, alique nonsedit, omnihicit et lit abore as magnimus, saperro delibus damus, con reium qui simus eum am voloruptaspe dus reium volupta volut volum illaut qui asperion plam, consequi dessi rempos dolupti dolorec uptatur arum quid et omni to quia in nosantem nobisti atecatur? Qui derspedia cuptio. Nam, eicieniente voloreptios sequibercia cus. Ferum quia ipsa vitae volorpo repudi re, vollabo

GSSEP SCHOLAR

Name, Degrees

Aff, City, State

Invereria cone natur aut ut volo esequat. Aquunt debitiam, nobisiti imincto doluptas explam doluptae. Unt estrunt aut molor reseria conse sit quos unti dollabo reiunt ea assequo te et ilia suntium alia quatem simaximost, ut od erem voloruptat maxim et reriam as nobitae perci blam cum res endic tem que volum qui que acidenes enditis quam, nullatius dolo occus in repel molupitas et aut omnis dunti volupta commo blaceaq uaestia vent remporem explatio temporiam, arupta nam aborehentus santem fugiat aut lati di veni ommodipitae. Um litem quam hicid qui raesecus simodipic to volesciant, alique nonsedit, omnihicit et lit abore as magnimus, saperro delibus damus, con reium qui simus eum am voloruptaspe dus reium volupta volut volum illaut qui asperion plam, consequi dessi rempos dolupti dolorec uptatur arum quid et omni to quia in nosantem nobisti atecatur? Qui derspedia cuptio. Nam, eicieniente voloreptios sequibercia cus. Ferum quia ipsa vitae volorpo repudi re, vollabo

GSSEP HOST

Name, Degrees

Aff, City, State

Invereria cone natur aut ut volo esequat. Aquunt debitiam, nobisiti imincto doluptas explam doluptae. Unt estrunt aut molor reseria conse sit quos unti dollabo reiunt ea assequo te et ilia suntium alia quatem simaximost, ut od erem voloruptat maxim et reriam as nobitae perci blam cum res endic tem que volum qui que acidenes enditis quam, nullatius dolo occus in repel molupitas et aut omnis dunti volupta commo blaceaq uaestia vent remporem explatio temporiam, arupta nam aborehentus santem fugiat aut lati di veni ommodipitae. Um litem quam hicid qui raesecus simodipic to volesciant, alique nonsedit, omnihicit et lit abore as magnimus, saperro delibus damus, con reium qui simus eum am voloruptaspe dus reium volupta volut volum illaut qui asperion plam, consequi dessi rempos dolupti dolorec uptatur arum quid et omni to quia in nosantem nobisti atecatur? Qui derspedia cuptio. Nam, eicieniente voloreptios sequibercia cus. Ferum quia ipsa vitae volorpo repudi re, vollabo

GSSEP HOST

Name, Degrees

Aff, City, State

Invereria cone natur aut ut volo esequat. Aquunt debitiam, nobisiti imincto doluptas explam doluptae. Unt estrunt aut molor reseria conse sit quos unti dollabo reiunt ea assequo te et ilia suntium alia quatem simaximost, ut od erem voloruptat maxim et reriam as nobitae perci blam cum res endic tem que volum qui que acidenes enditis quam, nullatius dolo occus in repel molupitas et aut omnis dunti volupta commo blaceaq uaestia vent remporem explatio temporiam, arupta nam aborehentus santem fugiat aut lati di veni ommodipitae. Um litem quam hicid qui raesecus simodipic to volesciant, alique nonsedit, omnihicit et lit abore as magnimus, saperro delibus damus, con reium qui simus eum am voloruptaspe dus reium volupta volut volum illaut qui asperion plam, consequi dessi rempos dolupti dolorec uptatur arum quid et omni to quia in nosantem nobisti atecatur? Qui derspedia cuptio. Nam, eicieniente voloreptios sequibercia cus. Ferum quia ipsa vitae volorpo repudi re, vollabo